Scientific Advisory Board
The Scientific Advisory Board (SAB) for the CRUK Barts Centre consists of an international group of the distinguished scientists and clinician scientists and is designed to provide an independent and expert view on the research, innovation and development of the Centre.
John Bell, PhD
Chair
Professor of Medicine, The University of Ottawa
Dr John Bell is a member of the Center for Cancer Therapeutics at The Ottawa Hospital Cancer Center, a Senior Scientist with the Ottawa Hospital Research Institute and Professor of Medicine at the University of Ottawa. He is Director of the Canadian Oncolytic Virus Consortium, a Terry Fox funded group from across Canada that is developing virus based cancer therapeutics, and Program Co-Director of the Immunotherapeutics Program for the Ontario Institute for Cancer Research. He is the Scientific Director of BioCanRx, a Network of Centres of Excellence for the development of Biotherapeutics for Cancer Therapy and is a fellow of the Royal Society of Canada.
Margaret Frame, OBE, PhD
Director, Cancer Research UK Edinburgh Centre
Director, MRC Institute of Genetics and Molecular Medicine
Margaret Frame is Professor of Cancer Research, Science Director of the Cancer Research UK Edinburgh Cancer Centre and Director of the MRC Institute of Genetics and Molecular Medicine. She recently served as President of the British Association for Cancer Research and Chaired the 2018 National (UK) Cancer Research Institute meeting. Professor Frame is currently co-Chair of the Academy of Medical Sciences Careers Committee and a member of the Lister Institute Scientific Advisory Committee, Wellcome Trust Expert Review Group and ERC Funding Panel. She was awarded an OBE in the Queen’s Honours List in 2018 for services to cancer research.
Gareth Evans, MD FCRP
Professor of Medical Genetics and Cancer Epidemiology, The University of Manchester
Professor Gareth Evans has established a national and international reputation in clinical and research aspects of cancer genetics, particularly in neurofibromatosis and breast cancer. He has developed a clinical service for cancer genetics in the North West Region of England, which is nationally regarded. He is an important opinion leader nationally through membership of committees and was chairman of the NICE Familial Breast Cancer Guideline Development Group (2002-2010) and is now clinical lead (2011-).
Matt Smalley, PhD
Director, European Cancer Stem Cell Research Institute, Cardiff University
Professor Matt Smalley became Director of the European Cancer Stem Cell Research Institute, Cardiff University, in 2018. He is Associate Theme Lead for the Cardiff University College of Biological and Life Sciences Cancer Theme and Deputy Head of the Division of Biomedicine, School of Biosciences. Professor Smalley’s laboratory group are working to understand how the combination of different tumour-initiating genetic lesions occurring in different normal stem and progenitor cells drive cancer heterogeneity.
René Bernards, PhD
Division of Molecular Carcinogenesis, Netherlands Cancer Institute
René Bernards is a Group Leader at the Netherlands Cancer Institute and Professor of Molecular Carcinogenesis at Utrecht University, The Netherlands. His scientific accomplishments include the development of MammaPrint, the first clinically-used gene expression profile for breast cancer. To bring this discovery to the clinic he co-founded "Agendia," a genomics-based diagnostic company that started offering the first microarray-based diagnostic test for the clinical management of breast cancer in 2004.